Found 585 with Last Name = 'bhosale' and Initial = 'vm' 
Affinity DataIC50: 0.615nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 1.45nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 1.68nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.98nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 2.15nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.18nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 2.21nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 2.49nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 2.93nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.18nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.34nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.38nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.54nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.63nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 3.98nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.02nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.16nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 4.26nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.40nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.52nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.84nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 4.84nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.06nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.15nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.29nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.29nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.35nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.37nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 5.52nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.60nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.61nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 5.96nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 5.99nMAssay Description:The assay is based on the principle that binding of the agonist to the RORγ causes a conformational change around helix 12 in the ligand binding...More data for this Ligand-Target Pair
TargetAlcohol dehydrogenase class-3(Homo sapiens (Human))
Glenmark Pharmaceuticals Limited
Curated by ChEMBL
Glenmark Pharmaceuticals Limited
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Inhibition of human GSNOR assessed as reduction in NADH consumption after 3 mins by spectrophotometric analysisMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 6.28nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 6.49nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 6.65nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 6.74nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 6.91nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
Affinity DataIC50: 7.10nMAssay Description:Inhibition of mouse GSNOR assessed as reduction in NADH consumption after 3 mins by spectrophotometric analysisMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 7.10nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 7.58nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 7.67nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 8.04nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 8.36nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 8.54nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily M member 8(Homo sapiens (Human))
Glenmark Pharmaceuticals Ltd.
Curated by ChEMBL
Glenmark Pharmaceuticals Ltd.
Curated by ChEMBL
Affinity DataIC50: 8.90nMAssay Description:Antagonist activity at human TRPM8 expressed in CHO cells assessed as inhibition of icilin-induced 45Ca2+ uptake incubated for 10 mins prior to icili...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 8.92nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily A member 1(Homo sapiens (Human))
GLENMARK PHARMACEUTICALS S.A.
US Patent
GLENMARK PHARMACEUTICALS S.A.
US Patent
Affinity DataIC50: 9.04nMT: 2°CAssay Description:The inhibition of TRPA1 receptor activation was measured as inhibition of allylisothiocyanate (AITC) induced cellular uptake of radioactive calcium. ...More data for this Ligand-Target Pair
TargetAlcohol dehydrogenase class-3(Rattus norvegicus)
Glenmark Pharmaceuticals Limited
Curated by ChEMBL
Glenmark Pharmaceuticals Limited
Curated by ChEMBL
Affinity DataIC50: 9.10nMAssay Description:Inhibition of rat GSNOR assessed as reduction in NADH consumption after 3 mins by spectrophotometric analysisMore data for this Ligand-Target Pair
